Expertise in
23
conditions

Dr. Andrew P. Dalovisio

Hematology Oncology | Hematology | Oncology
Mary Bird Perkins Cancer Center
4950 Essen Ln, 
Baton Rouge, LA 
Accepting New Patients
16 Years of Experience
Expertise in
23
conditions
Mary Bird Perkins Cancer Center
4950 Essen Ln, 
Baton Rouge, LA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Andrew Dalovisio is a Hematologist Oncology specialist and a Hematologist in Baton Rouge, Louisiana. Dr. Dalovisio has been practicing medicine for over 16 years is highly rated in 23 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Dalovisio is currently accepting new patients.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2009
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IL
Hospital Affiliations
Ochsner Medical Center Acute
Baton Rouge General Medical Center
Ochsner Medical Center - Baton Rouge
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

MARY BIRD PERKINS CANCER CENTER
4950 Essen Ln, Baton Rouge, LA 70809

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Enrollment Status: Terminated
Publish Date: November 15, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Drug
Study Drugs: Alvocidib, Cytarabine
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
View 4 Less Clinical Trials

6 Total Publications

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
Journal: Nature medicine
Published: May 10, 2023
Similar Doctors
Expertise in
67
conditions
Dr. Gerald P. Miletello
Oncology | Hematology Oncology | Hematology
Expertise in
67
conditions
Dr. Gerald P. Miletello
Oncology | Hematology Oncology | Hematology

Our Lady Of The Lake Physician Group LLC

7777 Hennessy Blvd, Suite 6000, 
Baton Rouge, LA 
 (0.3 miles away)
225-757-0343
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Gerald Miletello is an Oncologist and a Hematologist Oncology provider in Baton Rouge, Louisiana. Dr. Miletello is highly rated in 67 conditions, according to our data. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Colorectal Cancer, Septoplasty, and Bone Marrow Aspiration. Dr. Miletello is currently accepting new patients.

Expertise in
14
conditions
Dr. Shaista H. Faruqui
Hematology Oncology | Hematology | Oncology
Expertise in
14
conditions
Dr. Shaista H. Faruqui
Hematology Oncology | Hematology | Oncology
5320 Dijon Dr, 
Baton Rouge, LA 
 (0.5 miles away)
225-769-2161
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Shaista Faruqui is a Hematologist Oncology specialist and a Hematologist in Baton Rouge, Louisiana. Dr. Faruqui is highly rated in 14 conditions, according to our data. Her top areas of expertise are Idiopathic Neutropenia, Chronic Familial Neutropenia, Immune Thrombocytopenic Purpura (ITP), and Adult Immune Thrombocytopenia. Dr. Faruqui is currently accepting new patients.

Expertise in
54
conditions
Dr. Jack E. Saux
Hematology Oncology | Hematology | Oncology
Expertise in
54
conditions
Dr. Jack E. Saux
Hematology Oncology | Hematology | Oncology

Mary Bird Perkins Cancer Center

4950 Essen Ln, Suite 200, 
Baton Rouge, LA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jack Saux is a Hematologist Oncology specialist and a Hematologist in Baton Rouge, Louisiana. Dr. Saux is highly rated in 54 conditions, according to our data. His top areas of expertise are Paget Disease of the Breast, Familial Colorectal Cancer, Breast Cancer, and Angiosarcoma. Dr. Saux is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dalovisio's expertise for a condition
ConditionClose
    View All 18 Advanced Conditions
    View All 66 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile